Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality.
作者信息
Karaboyas Angelo, Port Friedrich K, Massy Ziad A, Locatelli Francesco, Cases Aleix, Nitta Kosaku, Liabeuf Sophie, Jager Kitty J, Robinson Bruce M
机构信息
Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Ambroise Paré University Hospital, Assistance publique Hôpitaux de Paris, Department of Nephrology Boulogne-Billancourt/Paris, and Institut national de la santé et de la recherche médicale Unit 1018, Team 5, CESP, Saclay University, and Versailles Saint-Quentin-en-Yvelines University, Paris-Ile-de-France-West University, Villejuif, France.
出版信息
Kidney Int Rep. 2020 Oct 10;6(1):214-218. doi: 10.1016/j.ekir.2020.10.003. eCollection 2021 Jan.
Abstract
摘要
相似文献
1
Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality.
Kidney Int Rep. 2020 Oct 10;6(1):214-218. doi: 10.1016/j.ekir.2020.10.003. eCollection 2021 Jan.
2
Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18.
3
De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma.
Int J Clin Pharm. 2015 Dec;37(6):1033-7. doi: 10.1007/s11096-015-0201-5. Epub 2015 Sep 25.
4
Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?
Kidney Int Rep. 2019 Jul 11;4(9):1199-1202. doi: 10.1016/j.ekir.2019.07.004. eCollection 2019 Sep.
5
Administration of erythropoiesis-stimulating agents in patients undergoing haemodialysis: A time and motion study.
J Ren Care. 2017 Dec;43(4):219-225. doi: 10.1111/jorc.12213. Epub 2017 Sep 12.
6
Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
J Am Soc Nephrol. 2019 Jun;30(6):1037-1048. doi: 10.1681/ASN.2018101007. Epub 2019 Apr 23.
7
Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Am J Hematol. 2010 Nov;85(11):838-43. doi: 10.1002/ajh.21837.
8
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28.
9
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.
Crit Rev Oncol Hematol. 2018 Sep;129:79-90. doi: 10.1016/j.critrevonc.2018.06.010. Epub 2018 Jun 19.
10
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
PLoS One. 2020 Apr 17;15(4):e0231830. doi: 10.1371/journal.pone.0231830. eCollection 2020.
引用本文的文献
1
Effect of erythropoiesis-stimulating agent types on malignancy in hemodialysis patients.
Clin Kidney J. 2025 Jun 16;18(6):sfaf148. doi: 10.1093/ckj/sfaf148. eCollection 2025 Jun.
2
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
Nephrology (Carlton). 2025 May;30(5):e70046. doi: 10.1111/nep.70046.
3
Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With NonDialysis-Dependent CKD: A Post Hoc Regional Analysis of the PROTECT Randomized Clinical Trial of ESA-Treated Patients.
Kidney Med. 2023 May 12;5(7):100667. doi: 10.1016/j.xkme.2023.100667. eCollection 2023 Jul.
4
Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress.
Oxid Med Cell Longev. 2022 Apr 14;2022:9598211. doi: 10.1155/2022/9598211. eCollection 2022.
5
Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial.
J Hematol. 2021 Dec;10(6):255-265. doi: 10.14740/jh862. Epub 2021 Nov 29.
6
ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
J Clin Med. 2021 Feb 18;10(4):839. doi: 10.3390/jcm10040839.
本文引用的文献
1
Analysis of Other Confounding Factors Is Mandatory before Considering That Long-Acting Erythropoiesis Stimulating Agents Are Deleterious to Patients on Dialysis.
J Am Soc Nephrol. 2019 Sep;30(9):1771. doi: 10.1681/ASN.2019050505. Epub 2019 Aug 16.
2
ESA Resistance May Be a Potential Confounder for Mortality among Different ESA Types.
J Am Soc Nephrol. 2019 Sep;30(9):1772. doi: 10.1681/ASN.2019060556. Epub 2019 Aug 16.
3
Equivalent Doses Matter, Rather Than Types.
J Am Soc Nephrol. 2019 Sep;30(9):1772-1773. doi: 10.1681/ASN.2019060569. Epub 2019 Aug 16.
4
Erythropoiesis-Stimulating Agents and Mortality.
J Am Soc Nephrol. 2019 Jun;30(6):907-908. doi: 10.1681/ASN.2019030266. Epub 2019 Apr 23.
5
Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
J Am Soc Nephrol. 2019 Jun;30(6):1037-1048. doi: 10.1681/ASN.2018101007. Epub 2019 Apr 23.
6
Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
Adv Ther. 2016 Apr;33(4):610-25. doi: 10.1007/s12325-016-0309-6. Epub 2016 Mar 10.
7
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2.
8
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28.
9
Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study.
Kidney Int Suppl. 2008 Dec(111):S82-7. doi: 10.1038/ki.2008.524.
Zotero 插件